The ACSO Post: Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial
<p>Virginia Kaklamani, MD, Medical Oncology, was quoted in this story. Read More</p>
<p>Virginia Kaklamani, MD, Medical Oncology, was quoted in this story. Read More</p>
Share This Story
<p>Virginia Kaklamani, MD, Medical Oncology, was quoted in this story. Read More</p>
Share This Story
<p>Ralph Riviello, MD, MS, FACEP, chair of Department of Emergency Medicine, was quoted in this story. Read More</p>
Share This Story
<p>Ralph Riviello, MD, MS, FACEP, chair of Department of Emergency Medicine, was quoted in this story. Read More</p>
Share This Story
<p>Ralph Riviello, MD, MS, FACEP, chair of Department of Emergency Medicine, was included in this story via a link to his interview with KSAT. Read More</p>
Share This Story
<p>Ralph Riviello, MD, MS, FACEP, chair of Department of Emergency Medicine, was quoted in this news segment. Read More</p>
Share This Story
<p>Ralph Riviello, MD, MS, FACEP, chair of Department of Emergency Medicine, was quoted in this story. Read More</p>
Share This Story
<p>Monica Verduzco-Gutierrez, MD, Physical Medicine and Rehabilitation, was quoted in this story. Read More</p>
Share This Story
<p>Arash Salardini, MD, Neurology, was quoted in this story. Read More</p>
Share This Story
<p>Jose Cadena Zuluaga, MD, Infectious Diseases, was quoted in this news segment. Read More </p>
Share This Story